evidence: After 4 weeks of treatment, all doses of AZD3199 had increased mean peak and trough FEV1 values compared with placebo, but no clear dose–response was observed (Figure 2);
intervention: AZD3199 (200, 400 or 800 μg o.d.)
comparator: formoterol (9 μg b.i.d.)
outcome: Forced vital capacity (FVC)